非ステロイド性抗炎症薬は,Rhoを阻害することによって,アミロイド原性Abeta42を低下させることができます
1Neuroscience Discovery Research and Bioresearch Technologies and Proteins, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA. zhou_yan_yz@lilly.com
Science (New York, N.Y.)
|November 15, 2003
まとめ
特定の非ステロイド性抗炎症薬 (NSAIDs) は,Rho関連キナーゼ (ROCK) 経路を阻害することによって,アミロイドベータ42 (Abeta42) を低下させます. この経路は,アミロイド前駆体タンパク質の処理を調節し,アルツハイマー病の新たな治療標的を提供している.
科学分野:
- バイオケミストリー バイオケミストリー
- 神経科学は神経科学である.
- 薬理学 薬理学とは
背景:
- アミロイドベータ42 (Abeta42) は,アルツハイマー病の病原性における重要なペプチドである.
- 特定の非ステロイド性抗炎症薬 (NSAIDs) は,Abeta42の分泌を減少させる能力を示しています.
- このNSAID効果の背後にある正確な分子機構は,まだ完全に理解されていません.
研究 の 目的:
- Abeta42の産生を調節するRho関連キナーゼ (ROCK) 経路の役割を調査する.
- Abeta42を阻害するNSAIDが,ROCK経路の阻害によってそうするかどうかを判断する.
- アルツハイマー病モデルの脳Abeta42レベルを低下させるためのROCK阻害の治療の可能性を評価する.
主な方法:
- アベタ42の分泌を測定するインビトロアッセイ.
- 特定の阻害剤を使用したRhoおよびRho関連キナーゼ (ROCK) の抑制.
- アルツハイマー病のトランスジェニックマウスモデルに選択的なROCK阻害剤 (Y-27632) を投与.
- 治療されたマウスにおける脳Abeta42レベルの定量化.
主要な成果:
- RhoとROCKは,試験管内でAbeta42の産生を優先的に調節することが判明しました.
- Rho抑制活性を示すNSAIDのみが,Abeta42.2を下げるのに効果的であった.
- Y-27632による選択的ROCK阻害は,変異性アルツハイマー病のマウスモデルにおける脳Abeta42レベルを著しく低下させた.
結論:
- Rho-ROCK経路は,アミロイド前駆体タンパク質の処理とAbeta42生成の調節に関与しています.
- NSAIDのサブセットは,Rho活性を抑制することによって,Abeta42を減少させる可能性があります.
- Rho-ROCK経路を標的にすることは,アルツハイマー病におけるAbeta42を減らすための潜在的な治療戦略です.
関連する概念動画
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...